VTYX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ventyx Biosciences Inc

NASDAQ | VTYX

6.47

USD

$0.00

(

0.00%

)

At Close (As of Oct 24, 2025)

$470.64M

Market Cap

-

P/E Ratio

-1.66

EPS

$7.82

52 Week High

$0.78

52 Week Low

HEALTHCARE

Sector

VTYX Chart

Recent Chart
Price Action

VTYX Technicals

Tags:

VTYX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$135M
Ebitda -$134M
Net Income -$135M

Revenue & Profitability

Earnings Performance

VTYX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $277M
Total Current Assets $230M
Cash And Cash Equivalents At Carrying Value $27M
Cash And Short Term Investments $27M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $47M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $36M
Short Term Investments $190M
Other Current Assets $11M
Other Non Current Assets -
Total Liabilities $23M
Total Current Liabilities $13M
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt $2.1M
Total Non Current Liabilities $9.7M
Capital Lease Obligations $11M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $11M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $254M
Treasury Stock -
Retained Earnings -$554M
Common Stock $7K
Common Stock Shares Outstanding $68M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$131M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.3M
Capital Expenditures $241K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$16M
Cashflow From Financing $122M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$135M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$135M
Ebitda -$134M
Net Income -$135M

VTYX News

VTYX Profile

Ventyx Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, dedicated to developing novel small molecule therapeutics for inflammatory and autoimmune disorders. The company is advancing a promising pipeline of drug candidates that target critical pathways involved in these diseases, aiming to meet substantial unmet medical needs. With a robust emphasis on research and development, Ventyx is well-positioned to provide innovative treatment solutions that can improve patient outcomes and capitalize on emerging opportunities within the dynamic biopharmaceutical market.

WGRX
+200.32%
$1.21
BYND
-9.57%
$2.56
TOVX
+95.58%
$0.66
YYAI
-15.09%
$0.07
VIVK
+50.80%
$0.39
CGBS
-39.47%
$0.03
F
+10.29%
$13.61
YDKG
-16.43%
$0.06
VHAI
0.00%
$0.00
INTC
+0.27%
$38.26
BURU
-5.27%
$0.34
T
-3.63%
$24.62
BITF
+5.71%
$4.16
DVLT
+42.88%
$3.21
NEUP
+54.07%
$6.24
AXDX
-61.36%
$0.03
ADTX
-5.15%
$0.28
NVDA
+1.66%
$185.18
AAL
+8.00%
$13.79
PLUG
-1.36%
$2.88
RGTI
+2.39%
$40.54
QUBT
+7.19%
$15.94
VZ
-3.51%
$38.40
SCNX
-36.15%
$1.65
QLGN
+14.16%
$4.03
TSLA
-2.32%
$438.55
JOBY
+1.29%
$15.67
QBTS
+8.75%
$33.77
NOK
+1.54%
$6.26
RIG
+2.69%
$3.99
AMD
+6.14%
$249.42
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ONDS
+9.06%
$7.70
SRM
+53.27%
$10.30
SOFI
+3.93%
$29.18
AMC
-0.72%
$2.73
ADAP
-4.14%
$0.06
NIO
+0.73%
$6.89
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
WTO
-10.78%
$0.06
ETHD
-0.62%
$3.94
CAN
+4.82%
$1.84
LUV
-6.25%
$31.65
ETWO
0.00%
$3.30
DNN
+2.19%
$2.79
AIRE
-16.85%
$0.81
ASST
+6.45%
$0.92
CLOV
+18.90%
$3.80
AFMD
-34.94%
$0.18
CIFR
+18.34%
$20.42
IREN
+8.57%
$60.65
PLTR
+2.77%
$185.49
GRAB
+2.06%
$5.83
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
SNAP
+0.50%
$7.91
NUAI
+31.13%
$5.18
LAES
+8.93%
$6.23
IONZ
-6.75%
$3.71
QS
+9.82%
$16.10
PBR
+0.08%
$11.85
GPUS
-0.23%
$0.38
RANI
-13.45%
$2.09
OPI
-16.97%
$0.20
RXRX
+1.65%
$5.82
KLG
-9.05%
$13.35
AMZN
+1.62%
$224.69
NVTS
+7.71%
$14.66
RGTZ
-4.72%
$14.19
GRYP
-10.38%
$1.38
BBD
-0.10%
$3.34
GNTA
+96.59%
$6.35
MODV
-25.22%
$0.43
IONQ
+3.96%
$61.72
UUUU
-0.11%
$21.23
ACHR
+4.85%
$11.44
HIMS
+2.17%
$48.49
RF
+1.97%
$24.57
MARA
+1.90%
$19.58
NRXS
-5.10%
$3.62
TLRY
+1.35%
$1.50
UBER
+2.60%
$94.61
ABEV
0.00%
$2.21
DFLI
+12.38%
$1.27
RR
+9.31%
$5.92
GOOGL
+3.14%
$261.05
XFOR
+25.19%
$3.86
ERIC
-0.36%
$9.44
HOOD
+3.45%
$138.96
MSAI
-36.83%
$0.85
WU
+0.12%
$8.14
WULF
+8.02%
$13.91
XOM
+1.10%
$115.98
BAC
+1.87%
$52.72
CRWV
+1.48%
$123.34
SAND
-6.04%
$12.12
BTBT
+4.56%
$3.89
AAPL
+1.41%
$263.24
WGRX
+200.32%
$1.21
BYND
-9.57%
$2.56
TOVX
+95.58%
$0.66
YYAI
-15.09%
$0.07
VIVK
+50.80%
$0.39
CGBS
-39.47%
$0.03
F
+10.29%
$13.61
YDKG
-16.43%
$0.06
VHAI
0.00%
$0.00
INTC
+0.27%
$38.26
BURU
-5.27%
$0.34
T
-3.63%
$24.62
BITF
+5.71%
$4.16
DVLT
+42.88%
$3.21
NEUP
+54.07%
$6.24
AXDX
-61.36%
$0.03
ADTX
-5.15%
$0.28
NVDA
+1.66%
$185.18
AAL
+8.00%
$13.79
PLUG
-1.36%
$2.88
RGTI
+2.39%
$40.54
QUBT
+7.19%
$15.94
VZ
-3.51%
$38.40
SCNX
-36.15%
$1.65
QLGN
+14.16%
$4.03
TSLA
-2.32%
$438.55
JOBY
+1.29%
$15.67
QBTS
+8.75%
$33.77
NOK
+1.54%
$6.26
RIG
+2.69%
$3.99
AMD
+6.14%
$249.42
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ONDS
+9.06%
$7.70
SRM
+53.27%
$10.30
SOFI
+3.93%
$29.18
AMC
-0.72%
$2.73
ADAP
-4.14%
$0.06
NIO
+0.73%
$6.89
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
WTO
-10.78%
$0.06
ETHD
-0.62%
$3.94
CAN
+4.82%
$1.84
LUV
-6.25%
$31.65
ETWO
0.00%
$3.30
DNN
+2.19%
$2.79
AIRE
-16.85%
$0.81
ASST
+6.45%
$0.92
CLOV
+18.90%
$3.80
AFMD
-34.94%
$0.18
CIFR
+18.34%
$20.42
IREN
+8.57%
$60.65
PLTR
+2.77%
$185.49
GRAB
+2.06%
$5.83
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
SNAP
+0.50%
$7.91
NUAI
+31.13%
$5.18
LAES
+8.93%
$6.23
IONZ
-6.75%
$3.71
QS
+9.82%
$16.10
PBR
+0.08%
$11.85
GPUS
-0.23%
$0.38
RANI
-13.45%
$2.09
OPI
-16.97%
$0.20
RXRX
+1.65%
$5.82
KLG
-9.05%
$13.35
AMZN
+1.62%
$224.69
NVTS
+7.71%
$14.66
RGTZ
-4.72%
$14.19
GRYP
-10.38%
$1.38
BBD
-0.10%
$3.34
GNTA
+96.59%
$6.35
MODV
-25.22%
$0.43
IONQ
+3.96%
$61.72
UUUU
-0.11%
$21.23
ACHR
+4.85%
$11.44
HIMS
+2.17%
$48.49
RF
+1.97%
$24.57
MARA
+1.90%
$19.58
NRXS
-5.10%
$3.62
TLRY
+1.35%
$1.50
UBER
+2.60%
$94.61
ABEV
0.00%
$2.21
DFLI
+12.38%
$1.27
RR
+9.31%
$5.92
GOOGL
+3.14%
$261.05
XFOR
+25.19%
$3.86
ERIC
-0.36%
$9.44
HOOD
+3.45%
$138.96
MSAI
-36.83%
$0.85
WU
+0.12%
$8.14
WULF
+8.02%
$13.91
XOM
+1.10%
$115.98
BAC
+1.87%
$52.72
CRWV
+1.48%
$123.34
SAND
-6.04%
$12.12
BTBT
+4.56%
$3.89
AAPL
+1.41%
$263.24
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.